Board Of Directors

Committees:

• Value Creation

Attributes and Skills Provided to the Board:

• Executive leadership experience at healthcare and life sciences companies
• Global business experience
• Investment stewardship experience
• Growth strategies and market expansion
• Operational experience in capital-intensive, innovation-focused industries

Expertise Provided to the Board:

John Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He has two decades of experience leading global companies in life sciences, medical devices, and diagnostics.

Prior to joining the company, Mr. Marotta served as Executive in Residence of Patient Square Capital, a leading healthcare investment firm. Previously, he served as CEO and President of PHC Holdings Corp. (TSE: 6523) (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues, and leading its IPO from owners KKR Capital. He also held a variety of senior executive roles in leading life sciences companies, including Danaher (NYSE: DHR), Envista Holdings (NYSE: NVST), and Cardinal Health (NYSE: CAH), where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions. Mr. Marotta began his career in sales leadership roles for therapeutics and medical device offerings.

Mr. Marotta received his BS from the University of Dayton and his MBA from the University of Denver, Daniels School of Business.

Committees:

• Audit
• Nominating and Governance

Attributes and Skills Provided to the Board:

• Global business experience
• Financial management and accounting
• Audit
• Risk management and investment stewardship experience
• Financing transactions
• Mergers & acquisitions / integrations
• Experience in highly regulated industries

Expertise Provided to the Board:

Frank E. Casal is the Chair of the Azenta Board. He formerly served as Vice Chair of Audit of KPMG, where he spent over forty years of his career. Mr. Casal brings best-in-class knowledge of financial reporting, accounting and audit to the Azenta Board, drawing on his experience providing supervisory responsibilities to large, global Fortune 500 companies. Mr. Casal has significant expertise in transforming businesses through mergers and acquisitions, financing transactions and other strategic priorities, including Azenta’s split from Brooks Automation. Having led a division of almost 9,000 professionals at KPMG, he has proven leadership and management experience, offering unique perspective to the Azenta Board’s ongoing efforts to manage talent and human capital.

Committees:

• Value Creation
• Human Resources and Compensation

Attributes and Skills Provided to the Board:

• • Investment stewardship and corporate governance expertise
  • Public-company director and board committee leadership experience
  • Experience in fundamental valuation and corporate management analysis
  • Capital allocation expertise
  • Experience helping to enhance strategy, financial management and governance in the healthcare sector

Expertise Provided to the Board:

Quentin Koffey brings his expertise as a professional investor as Founder, Managing Partner and Chief Investment Officer of Politan Capital Management. Prior to founding Politan in 2021, Mr. Koffey was a partner at Senator Investment Group LP from 2019 to 2021, a Portfolio Manager for Strategic Investments at The D.E. Shaw Group from 2017 to 2019 and a Portfolio Manager at Elliott Management Corporation from 2010 to 2017.

Committees:

• Value Creation

Attributes and Skills Provided to the Board:

• • Leadership experience in life sciences and healthcare companies
  • Global business experience
  • Experience in highly regulated industries
  • Growth strategies and market expansion
  • Operational experience in capital-intensive, innovation-focused industries

Expertise Provided to the Board:

Alan J. Malus brings experience from his service as the former Corporate Executive Vice President of Thermo Fisher (NYSE: TMO), where he also formerly served as former President, Laboratory Products and Services. He also held various leadership positions and senior executive positions in finance, marketing, commercial development and operations since joining Thermo Fisher in 1998. Previously, Mr. Malus served as an independent director at PHC Holdings Corp. (TSE: 6523), a global healthcare company headquartered in Japan.

Committees:

• Value Creation (Chair)

Attributes and Skills Provided to the Board:

• • Operational experience in capital-intensive, innovation-focused industries
  • Growth strategies and market expansion
  • Investment stewardship expertise
  • Public-company director experience
  • Mergers & acquisitions / integrations
  • Experience in fundamental valuation and corporate management analysis
  • Information Security experience

Expertise Provided to the Board:

William L. Cornog brings his expertise as the former head of KKR Capstone, the portfolio operations team of KKR & Co. (NYSE: KKR). In addition to leading Capstone, Mr. Cornog chaired KKR’s portfolio management committees for the Americas, Europe, Asia, Infrastructure, Impact & Technology Growth and was a member of the Investment & Distribution and Valuation Committees. Currently, Mr. Cornog is a board member at Brightview Holdings Inc. (NYSE: BV) and LiveWire (NYSE: LVWR), where he also serves as Chairman of the Audit Committee and the Conflicts Committee.

Committees:

• Audit
• ESG

Attributes and Skills Provided to the Board:

• Investment stewardship expertise
• Experience in healthcare industry
• Public-company director experience
• Experience in fundamental valuation and corporate management analysis
• Experience in Environmental, Social and Governance (ESG) initiatives

Expertise Provided to the Board:

Edward P. Bousa brings over 37 years of experience in the investment business to the Azenta Board. Mr. Bousa previously spent over 20 years at Wellington Management where he was a Partner and Team Lead of Quality Value Investment Strategies and helped grow that team’s assets under management to over $90 billion. Mr. Bousa also has deep experience in the healthcare industry, leveraging his valuable investor perspective on the healthcare delivery market to advise the Azenta Board. He also has significant experience in fundamental valuation and corporate management analysis, having executed over 7,000 in-depth assessments of company management teams. Mr. Bousa is also a proven advocate of ESG initiatives, having led broad firm participation in ESG engagements at Wellington.

Committees:

• Finance (Chair)
• ESG

Attributes and Skills Provided to the Board:

• Leadership experience in life sciences and healthcare companies
• Global business experience
• Growth strategies and market expansion
• Public-company director and executive experience
• Mergers & acquisitions / integrations
• Operational experience in capital-intensive, innovation-focused industries

Expertise Provided to the Board:

Tina S. Nova is an industry veteran in life sciences, with deep experience in building and leading successful life science businesses from conception through IPO, including public-company CEO experience. She has deep insights into commercial operations, sales and marketing efforts, and also brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director that created value for shareholders. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, until its $600 million sale to Veracyte (NASDAQ: VCYT) in 2021, Molecular Stethoscope and Genoptix, which she co-founded and oversaw its $470 million sale to Novartis AG (NYSE: NVS) in 2011.

Committees:

• Nomination and Governance (Chair)
• Audit

Attributes and Skills Provided to the Board:

• Global business experience
• Public-company executive experience
• Financial management and accounting
• Audit
• Growth strategies and market expansion
• ESG
• Mergers & acquisitions / integrations
• Leadership and talent development

Expertise Provided to the Board:

Erica J. McLaughlin currently serves as Executive Vice President, CFO and Head of Corporate Strategy at Cabot Corporation (NYSE: CBT), a publicly traded manufacturer of specialty chemicals and performance materials. As a results-driven executive, Ms. McLaughlin brings extensive international business experience and expertise in financial areas and strategy and a strong background in accounting and audit. She also has significant experience in mergers, acquisitions and integrations, as well as industrial knowledge of life sciences, having served on Azenta’s Board during its transition from Brooks Automation. With proven general management and leadership experience at global organizations, she is well versed in best-practice corporate governance and sustainable growth strategies. Further, her experience both as the Inaugural Chairperson of Cabot’s Diversity and Inclusion Steering Committee and as Co-Chair of the Governance pillar at Cabot’s ESG executive management structure, give her valuable perspective on ESG, DEI and other matters top-of-mind for Azenta’s leadership..

Committees:

• Human Resources and Compensation
• Nominating and Governance
• Value Creation

Attributes and Skills Provided to the Board:

• Executive leadership experience at healthcare and life sciences companies
• Investment stewardship experience
• Public-company director and executive experience
• Global business experience
• Mergers & acquisitions/integrations
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise Provided to the Board:

Dr. Martin D. Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. An experienced public-company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member, he brings valuable operational insight and industry expertise to the Azenta Board. Dr. Madaus has a proven track record of creating shareholder value in both public and private life science companies. He has notable experience in strategy, mergers and acquisitions and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG).

Committees:

• Audit (Chair)
• Finance

Attributes and Skills Provided to Board:

• Executive leadership experience at healthcare and life sciences companies
• Public-company director and executive experience
• Global business experience
• Investment stewardship expertise
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise Provided to the Board:

Didier Hirsch is the former CFO of Agilent Technologies (NYSE: A), a publicly traded life sciences and diagnostics company. Mr. Hirsch is an experienced finance executive who brings a strong track record of successfully running large, complex and multinational finance functions to the Azenta Board. Mr. Hirsch has served on the Board of four other public companies, including as Chair of the Audit Committee, where he leveraged his significant financial and risk management experience. He also possesses substantial international experience and regulatory knowledge from previous work in the technology and semiconductor sectors.

Committees:

• ESG (Chair)
• Human Resources and Compensation

Attributes and Skills Provided to the Board:

• Leadership experience in life sciences and healthcare companies
• Public-company director and executive experience
• Global business experience
• Risk management and investment stewardship
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise Provided to the Board:

Michael Rosenblatt, MD currently services as Senior Partner of Flagship Pioneering, a major life sciences venture-capital firm that originates new biotech companies. Dr. Rosenblatt has deep leadership and executive experience in the biotechnology industry, including serving as Chief Medical Officer of Merck (NYSE: MRK) and having contributed to Moderna’s coronavirus vaccine efforts. He also has deep board-level and management team experience as a founding scientist, scientific advisory Board member and director of more than a dozen biopharmaceutical companies. Dr. Rosenblatt has significant academic leadership experience as a dean and professor at prestigious medical schools. He is also a renowned leader in the biotech space, including as a winner of the Fuller Albright Award, with extensive expertise in drug discovery and medical research. He brings unique industry insights to the Azenta Board, particularly as it relates to the customer perspective, research and development, as well as opportunities in the marketplace.

Committees:

• Human Resources and Compensation (Chair)
• Finance

Attributes and Skills Provided to the Board:

• Leadership experience in life sciences and healthcare companies
• Risk management and investment stewardship experience
• Operational experience in capital-intensive, innovation-focused industries
• Growth strategies and market expansion
• Mergers & acquisitions / integrations
• Leadership and talent development

Expertise Provided to the Board:

As a Managing Director at AngelHealthcare Investors, an early-stage angel investment group focused on medical devices, life sciences and pharmaceutical companies, Robyn C. Davis brings valuable investor-focused perspective to the Azenta Board and its ongoing efforts to maximize shareholder value. She also has strong financial acumen, particularly as it relates to operational matters, and extensive experience supporting life sciences companies as they scale and grow, both organically and through mergers and acquisitions, having successfully exited certain portfolio companies and having sat on the Board of CRA Health when it was acquired by Volpara. She has more than three decades of independent C-suite consulting experience with both corporate and non-governmental organizations helping to lead value-creation strategies in growth, cost reduction, leadership and talent development. Ms. Davis also serves on the Boards of Psychemedics Corporation (NASDAQ: PMD), a developer of diagnostic tests, and Akston Biosciences Corporation, a manufacturer of veterinary protein therapeutics.

Committees:

• Value Creation

Attributes and Skills Provided to the Board:

• Executive leadership experience at healthcare and life sciences companies
• Global business experience
• Investment stewardship experience
• Growth strategies and market expansion
• Operational experience in capital-intensive, innovation-focused industries

Expertise Provided to the Board:

John Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He has two decades of experience leading global companies in life sciences, medical devices, and diagnostics.

Prior to joining the company, Mr. Marotta served as Executive in Residence of Patient Square Capital, a leading healthcare investment firm. Previously, he served as CEO and President of PHC Holdings Corp. (TSE: 6523) (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues, and leading its IPO from owners KKR Capital. He also held a variety of senior executive roles in leading life sciences companies, including Danaher (NYSE: DHR), Envista Holdings (NYSE: NVST), and Cardinal Health (NYSE: CAH), where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions. Mr. Marotta began his career in sales leadership roles for therapeutics and medical device offerings.

Mr. Marotta received his BS from the University of Dayton and his MBA from the University of Denver, Daniels School of Business.

Committees:

• Audit
• Nominating and Governance

Attributes and Skills Provided to the Board:

• Global business experience
• Financial management and accounting
• Audit
• Risk management and investment stewardship experience
• Financing transactions
• Mergers & acquisitions / integrations
• Experience in highly regulated industries

Expertise Provided to the Board:

Frank E. Casal is the Chair of the Azenta Board. He formerly served as Vice Chair of Audit of KPMG, where he spent over forty years of his career. Mr. Casal brings best-in-class knowledge of financial reporting, accounting and audit to the Azenta Board, drawing on his experience providing supervisory responsibilities to large, global Fortune 500 companies. Mr. Casal has significant expertise in transforming businesses through mergers and acquisitions, financing transactions and other strategic priorities, including Azenta’s split from Brooks Automation. Having led a division of almost 9,000 professionals at KPMG, he has proven leadership and management experience, offering unique perspective to the Azenta Board’s ongoing efforts to manage talent and human capital.

Committees:

• Value Creation
• Human Resources and Compensation

Attributes and Skills Provided to the Board:

• • Investment stewardship and corporate governance expertise
  • Public-company director and board committee leadership experience
  • Experience in fundamental valuation and corporate management analysis
  • Capital allocation expertise
  • Experience helping to enhance strategy, financial management and governance in the healthcare sector

Expertise Provided to the Board:

Quentin Koffey brings his expertise as a professional investor as Founder, Managing Partner and Chief Investment Officer of Politan Capital Management. Prior to founding Politan in 2021, Mr. Koffey was a partner at Senator Investment Group LP from 2019 to 2021, a Portfolio Manager for Strategic Investments at The D.E. Shaw Group from 2017 to 2019 and a Portfolio Manager at Elliott Management Corporation from 2010 to 2017.

Committees:

• Value Creation

Attributes and Skills Provided to the Board:

• • Leadership experience in life sciences and healthcare companies
  • Global business experience
  • Experience in highly regulated industries
  • Growth strategies and market expansion
  • Operational experience in capital-intensive, innovation-focused industries

Expertise Provided to the Board:

Alan J. Malus brings experience from his service as the former Corporate Executive Vice President of Thermo Fisher (NYSE: TMO), where he also formerly served as former President, Laboratory Products and Services. He also held various leadership positions and senior executive positions in finance, marketing, commercial development and operations since joining Thermo Fisher in 1998. Previously, Mr. Malus served as an independent director at PHC Holdings Corp. (TSE: 6523), a global healthcare company headquartered in Japan.

Committees:

• Value Creation (Chair)

Attributes and Skills Provided to the Board:

• • Operational experience in capital-intensive, innovation-focused industries
  • Growth strategies and market expansion
  • Investment stewardship expertise
  • Public-company director experience
  • Mergers & acquisitions / integrations
  • Experience in fundamental valuation and corporate management analysis
  • Information Security experience

Expertise Provided to the Board:

William L. Cornog brings his expertise as the former head of KKR Capstone, the portfolio operations team of KKR & Co. (NYSE: KKR). In addition to leading Capstone, Mr. Cornog chaired KKR’s portfolio management committees for the Americas, Europe, Asia, Infrastructure, Impact & Technology Growth and was a member of the Investment & Distribution and Valuation Committees. Currently, Mr. Cornog is a board member at Brightview Holdings Inc. (NYSE: BV) and LiveWire (NYSE: LVWR), where he also serves as Chairman of the Audit Committee and the Conflicts Committee.

Committees:

• Audit
• ESG

Attributes and Skills Provided to the Board:

• Investment stewardship expertise
• Experience in healthcare industry
• Public-company director experience
• Experience in fundamental valuation and corporate management analysis
• Experience in Environmental, Social and Governance (ESG) initiatives

Expertise Provided to the Board:

Edward P. Bousa brings over 37 years of experience in the investment business to the Azenta Board. Mr. Bousa previously spent over 20 years at Wellington Management where he was a Partner and Team Lead of Quality Value Investment Strategies and helped grow that team’s assets under management to over $90 billion. Mr. Bousa also has deep experience in the healthcare industry, leveraging his valuable investor perspective on the healthcare delivery market to advise the Azenta Board. He also has significant experience in fundamental valuation and corporate management analysis, having executed over 7,000 in-depth assessments of company management teams. Mr. Bousa is also a proven advocate of ESG initiatives, having led broad firm participation in ESG engagements at Wellington.

Committees:

• Finance (Chair)
• ESG

Attributes and Skills Provided to the Board:

• Leadership experience in life sciences and healthcare companies
• Global business experience
• Growth strategies and market expansion
• Public-company director and executive experience
• Mergers & acquisitions / integrations
• Operational experience in capital-intensive, innovation-focused industries

Expertise Provided to the Board:

Tina S. Nova is an industry veteran in life sciences, with deep experience in building and leading successful life science businesses from conception through IPO, including public-company CEO experience. She has deep insights into commercial operations, sales and marketing efforts, and also brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director that created value for shareholders. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, until its $600 million sale to Veracyte (NASDAQ: VCYT) in 2021, Molecular Stethoscope and Genoptix, which she co-founded and oversaw its $470 million sale to Novartis AG (NYSE: NVS) in 2011.

Committees:

• Nomination and Governance (Chair)
• Audit

Attributes and Skills Provided to the Board:

• Global business experience
• Public-company executive experience
• Financial management and accounting
• Audit
• Growth strategies and market expansion
• ESG
• Mergers & acquisitions / integrations
• Leadership and talent development

Expertise Provided to the Board:

Erica J. McLaughlin currently serves as Executive Vice President, CFO and Head of Corporate Strategy at Cabot Corporation (NYSE: CBT), a publicly traded manufacturer of specialty chemicals and performance materials. As a results-driven executive, Ms. McLaughlin brings extensive international business experience and expertise in financial areas and strategy and a strong background in accounting and audit. She also has significant experience in mergers, acquisitions and integrations, as well as industrial knowledge of life sciences, having served on Azenta’s Board during its transition from Brooks Automation. With proven general management and leadership experience at global organizations, she is well versed in best-practice corporate governance and sustainable growth strategies. Further, her experience both as the Inaugural Chairperson of Cabot’s Diversity and Inclusion Steering Committee and as Co-Chair of the Governance pillar at Cabot’s ESG executive management structure, give her valuable perspective on ESG, DEI and other matters top-of-mind for Azenta’s leadership..

Committees:

• Human Resources and Compensation
• Nominating and Governance
• Value Creation

Attributes and Skills Provided to the Board:

• Executive leadership experience at healthcare and life sciences companies
• Investment stewardship experience
• Public-company director and executive experience
• Global business experience
• Mergers & acquisitions/integrations
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise Provided to the Board:

Dr. Martin D. Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. An experienced public-company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member, he brings valuable operational insight and industry expertise to the Azenta Board. Dr. Madaus has a proven track record of creating shareholder value in both public and private life science companies. He has notable experience in strategy, mergers and acquisitions and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG).

Committees:

• Audit (Chair)
• Finance

Attributes and Skills Provided to Board:

• Executive leadership experience at healthcare and life sciences companies
• Public-company director and executive experience
• Global business experience
• Investment stewardship expertise
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise Provided to the Board:

Didier Hirsch is the former CFO of Agilent Technologies (NYSE: A), a publicly traded life sciences and diagnostics company. Mr. Hirsch is an experienced finance executive who brings a strong track record of successfully running large, complex and multinational finance functions to the Azenta Board. Mr. Hirsch has served on the Board of four other public companies, including as Chair of the Audit Committee, where he leveraged his significant financial and risk management experience. He also possesses substantial international experience and regulatory knowledge from previous work in the technology and semiconductor sectors.

Committees:

• ESG (Chair)
• Human Resources and Compensation

Attributes and Skills Provided to the Board:

• Leadership experience in life sciences and healthcare companies
• Public-company director and executive experience
• Global business experience
• Risk management and investment stewardship
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise Provided to the Board:

Michael Rosenblatt, MD currently services as Senior Partner of Flagship Pioneering, a major life sciences venture-capital firm that originates new biotech companies. Dr. Rosenblatt has deep leadership and executive experience in the biotechnology industry, including serving as Chief Medical Officer of Merck (NYSE: MRK) and having contributed to Moderna’s coronavirus vaccine efforts. He also has deep board-level and management team experience as a founding scientist, scientific advisory Board member and director of more than a dozen biopharmaceutical companies. Dr. Rosenblatt has significant academic leadership experience as a dean and professor at prestigious medical schools. He is also a renowned leader in the biotech space, including as a winner of the Fuller Albright Award, with extensive expertise in drug discovery and medical research. He brings unique industry insights to the Azenta Board, particularly as it relates to the customer perspective, research and development, as well as opportunities in the marketplace.

Committees:

• Human Resources and Compensation (Chair)
• Finance

Attributes and Skills Provided to the Board:

• Leadership experience in life sciences and healthcare companies
• Risk management and investment stewardship experience
• Operational experience in capital-intensive, innovation-focused industries
• Growth strategies and market expansion
• Mergers & acquisitions / integrations
• Leadership and talent development

Expertise Provided to the Board:

As a Managing Director at AngelHealthcare Investors, an early-stage angel investment group focused on medical devices, life sciences and pharmaceutical companies, Robyn C. Davis brings valuable investor-focused perspective to the Azenta Board and its ongoing efforts to maximize shareholder value. She also has strong financial acumen, particularly as it relates to operational matters, and extensive experience supporting life sciences companies as they scale and grow, both organically and through mergers and acquisitions, having successfully exited certain portfolio companies and having sat on the Board of CRA Health when it was acquired by Volpara. She has more than three decades of independent C-suite consulting experience with both corporate and non-governmental organizations helping to lead value-creation strategies in growth, cost reduction, leadership and talent development. Ms. Davis also serves on the Boards of Psychemedics Corporation (NASDAQ: PMD), a developer of diagnostic tests, and Akston Biosciences Corporation, a manufacturer of veterinary protein therapeutics.